NCT04668066View on ClinicalTrials.gov

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

December 27, 2022

Study Completion Date

December 27, 2022

Conditions
Atopic Dermatitis
Interventions
DRUG

PF-07242813

PF-07242813 given intravenously or subcutaneous

DRUG

Placebo

Placebo given intravenously or subcutaneous

Trial Locations (7)

74136

Vital Prospects Clinical Research Institute, PC, Tulsa

84058

Aspen Clinical Research, Orem

90033

Keck School of Medicine of USC, Los Angeles

USC/Norris Comprehensive Cancer Center, Los Angeles

92708

First OC Dermatology, Fountain Valley

92780

Orange County Research Center, Tustin

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04668066 - Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis | Biotech Hunter | Biotech Hunter